SYSTEMIC SCLEROSIS (SSC)

This study is testing whether a person's own fat tissue, processed to concentrate its regenerative cells, can improve hand function in people with systemic sclerosis (scleroderma). Researchers will inject these cells into the fingers of 48 participants and compare the results to …

This early study is testing the safety of a new drug called CC312 in adults with severe autoimmune diseases that have not improved with standard treatments. The drug works by engaging the body's own immune T cells to attack harmful B cells, using a mechanism similar to some advan…

This study is testing whether adding a new type of immune cell therapy (called AlloNK) to an existing drug (rituximab) can better control several autoimmune diseases that have come back after standard treatments. The trial will enroll 90 adults with rheumatoid arthritis, Sjögren'…

This early-stage study is testing the safety and initial effects of a new type of cell therapy for people with severe autoimmune diseases that haven't responded well to standard treatments. The therapy, called 'universal' CAR-T, uses donated immune cells engineered to target and …

This early-stage study is testing a single infusion of 'universal' CAR T-cells in adults with severe autoimmune diseases like lupus and scleroderma that have not improved with standard treatments. The therapy aims to target and remove harmful immune cells to potentially control t…

This is an early-stage study to check the safety of a new treatment called OL-CD19-GDT, a type of CAR-T cell therapy, for adults with severe autoimmune diseases that haven't responded to other treatments. The study will enroll 44 people with conditions like systemic sclerosis or …

This is an early-stage study testing a new type of cell therapy called BCMA/CD70 CAR-T for children with severe rheumatic diseases that have not responded to standard treatments. The trial aims to see if this therapy is safe and can reduce disease activity in conditions like juve…

This is an early-stage study testing a new, one-time treatment called TI-0032-III injection for people with severe autoimmune diseases that have not improved with standard medications. The treatment uses a single injection of genetic material to reprogram the patient's own immune…

This is an early-stage study to check the safety of a new cell therapy called YTS109 for adults with severe autoimmune diseases that have not responded to standard treatments. About 18 participants with conditions like lupus, scleroderma, or vasculitis will receive a single infus…

This study is testing whether a drug called efgartigimod, given as an injection under the skin, can help control the disease in adults with systemic sclerosis (scleroderma). About 81 participants will receive either the drug or a placebo for up to 48 weeks to see if it reduces sk…

This early-stage study is testing whether a therapy called CAR-T, which reprograms a patient's own immune cells, can help people with severe systemic sclerosis (scleroderma) that hasn't responded to other treatments. The goal is to see if this approach is safe and can reduce skin…

This study is testing whether an investigational drug called tibulizumab can help control systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage internal organs like the lungs. For the first 24 weeks, some participants will receive the drug while…

This is a first-in-human study to check the safety and early effects of an experimental cell therapy called FT819. It is for people aged 12-70 with moderate to severe forms of four serious autoimmune diseases (lupus, vasculitis, myositis, or scleroderma) that haven't responded we…

This early-stage study is testing a new cell therapy for people with severe autoimmune diseases that haven't improved with standard treatments. Doctors will give patients specially engineered immune cells (CAR-NK cells) to try to reset their overactive immune systems. The main go…

This early-stage study is testing a new treatment called CT1190B CAR-T cell therapy for adults with severe lupus or scleroderma that hasn't responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to potentially fight the disease, …

This study is testing a new blood test designed to predict which arthritis medications will work best for individual patients before they start treatment. Researchers will analyze blood samples from 120 people with various autoimmune rheumatic diseases to see if the test can accu…

This study aims to see if artificial intelligence (AI) can better screen for a serious lung complication called pulmonary arterial hypertension (PAH) in people with scleroderma. Researchers will compare new AI models against current screening methods using data from 350 patients.…

This study is testing a special exercise program called BETY, designed for people with scleroderma. The program aims to improve physical function, strength, and overall well-being by combining physical activity with psychological and social support. Researchers will enroll 48 chi…

This study is testing whether injecting a medication called sodium thiosulfate directly into painful calcium deposits under the skin can shrink them and reduce pain. It will involve about 20 adults with connective tissue diseases like scleroderma or dermatomyositis who have these…

This study is testing whether specific diets can help reduce severe bloating, abdominal pain, and other gut symptoms in people with systemic sclerosis (scleroderma). Researchers will compare three different dietary approaches in 60 participants to see which works best. The goal i…

This study is testing whether a lotion containing hemp extract (CBD) and urea works better than urea lotion alone to relieve severe itching in people with systemic sclerosis (scleroderma). It will involve 36 patients who will try both lotions to see which one better reduces itch,…

This study is testing whether a wearable device can help people with systemic sclerosis (scleroderma) manage their most troubling symptoms. 160 participants will wear either the real device or a look-alike version for 6 weeks to see if it reduces severe fatigue and painful Raynau…

This study aims to adapt and test a Turkish version of a questionnaire that lets people with scleroderma (systemic sclerosis) assess the thickness of the skin on their own arms. Researchers will enroll 50 adult patients to see if the Turkish version of the questionnaire is reliab…

This study aims to test new software that measures calcium deposits in the skin of people with scleroderma using CT scans. Researchers want to see if these detailed measurements match up with patients' reports of pain and disability. The goal is to create better tools for future …

This study aims to understand how scleroderma, a disease that hardens skin and tissues, affects a person's ability to chew and swallow food. Researchers will enroll 50 children and adults with scleroderma to measure their chewing and swallowing performance using simple tests and …

This study aims to understand the link between nutrition and disease activity in people with rheumatic diseases like rheumatoid arthritis and lupus. Researchers will assess the nutritional status of 460 patients using questionnaires and blood tests. The goal is to see if poor nut…

This study aims to find a way to predict which cancer patients might develop serious side effects from immunotherapy drugs. Researchers will compare blood samples from 300 cancer patients starting immunotherapy with samples from 40 people who have autoimmune diseases. They are lo…

This study aims to understand the relationship between physical abilities and the overall well-being of people living with scleroderma. Researchers will observe 50 children and adults with the condition, using walking tests, questionnaires, and other assessments. The goal is to g…

This study is tracking the long-term safety and effects of an experimental cell therapy called KYV-101 in people who have already received it. Researchers will follow 70 participants for up to 15 years to check for any delayed side effects and see how long the treatment's effects…